Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | BTK T474M |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| BTK T474M | Advanced Solid Tumor | predicted - resistant | Ibrutinib | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with Imbruvica (ibrutinib) failed to inhibit Btk activity in cell lines expressing BTK T474M in culture (PMID: 33526860). | 33526860 | |
| BTK T474M | Advanced Solid Tumor | predicted - resistant | Acalabrutinib | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with Calquence (acalabrutinib) failed to inhibit Btk activity in a cell line expressing BTK T474M in culture (PMID: 33526860). | 33526860 |